Opinion|Videos|November 20, 2026

When to Pause or Stop Therapy in Advanced RCC

Deciding when to pause or stop systemic therapy remains an open question in advanced RCC, with limited prospective data to guide clinicians.

Deciding when to pause or stop systemic therapy remains an open question in advanced RCC, with limited prospective data to guide clinicians. The panel discusses two scenarios for discontinuing ipilimumab plus nivolumab. One is a patient with an excellent response who develops severe immune-related toxicity, such as colitis requiring hospitalization. The other is a patient who completes planned maintenance nivolumab with durable disease control. Faculty describe a shared decision-making approach that often supports a treatment break, noting that patients who later relapse are not considered immunotherapy refractory and may be rechallenged. Stopping immunotherapy-TKI combinations calls for more caution, since complete responses appear less durable and recurrence after discontinuation tends to come sooner. Panelists express interest in intermittent TKI strategies to improve quality of life without compromising survival. They also suggest that a planned interruption can open a window for metastasis-directed therapy or nephrectomy in patients with a residual primary tumor.


Related to this article